DE
VRTX icon

DV Equities’s Vertex Pharmaceuticals VRTX Stock Holding History

DV Equities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$162K Buy
+358
New +$154K 0.03% 159

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

DV Equities's VRTX Position: Q4 2025 in Review

DV Equities opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2025: 358 shares worth $162K. The stake represents 0.03% of the portfolio and ranks #159 among its holdings.

1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • DV Equities held 358 shares of Vertex Pharmaceuticals worth $162K as of Q4 2025.
  • Vertex Pharmaceuticals was a new DV Equities position in Q4 2025.
  • Vertex Pharmaceuticals made up 0.03% of DV Equities's portfolio in Q4 2025, its #159 holding.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on DV Equities's 13F filing for Q4 2025, filed 17 Feb 2026.